Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we collect are used safely, ethically, and responsibly. Doing the right thing is core to who we are, what we do, and how we do it. We honor the trust placed in us by patients, customers, employees, shareholders, and communities.
Operate responsibly
We are committed to conducting ourselves with honesty, integrity, and respect for all
Doing the right thing is core to who we are
Practice strong corporate governance
By exercising strong corporate governance, we aim to inspire confidence in the work we do and in our company’s future.
Board of Directors
Our Board of Directors is a diverse group of leaders who champion scientific innovation. The Board’s aim is to ensure the company is equipped with the tools it needs to accelerate the power of genomics. The Board has adopted Corporate Governance Guidelines which are founded on a commitment to building shareholder value, with an emphasis on responsible governance. These guidelines, together with the Code of Conduct and Board Committee Charters, provide the framework for corporate governance at Illumina.
CSR governance
The full Board provides CSR oversight, and in 2022 we expanded the remit of the Nominating/Corporate Governance Committee to assist the Board in overseeing the Company's material corporate and social responsibility matters (CSR), except as specifically delegated to another Board committee.
Maintain a culture of compliance
At Illumina, our Code of Conduct and associated anti-bribery compliance policies and procedures are intended to promote honest and ethical conduct, compliance with applicable laws, and protection of our business interests. Our Anti-Bribery Compliance Program is built on the eight elements of an effective compliance program as recognized by the Office of Inspector General (OIG) of the US Department of Health and Human Services and the Serious Fraud Office (SFO) of the UK. The Program provides a comprehensive framework to detect and prevent violations of law and company policy.
Make responsible public policy decisions
Proactive engagement with public policy stakeholders enables the sharing of accurate and reliable information about genomics and advocacy for policies that ensure and promote broad access. Illumina participates in the political and public policy process with governments and organizations around the world to engage and educate policymakers and key stakeholders on issues that impact our mission and business.
Our interactions with policymakers must align with our core values, ethical responsibilities, and legal obligations. The Illumina Nominating/ Corporate Governance Committee of our Board of Directors oversees our political policies and contribution practices.
Advocating for public policies that ensure and enable broad access to genomic technologies is a priority. Our legislative priorities:
- Advancement of precision medicine
- Adoption and reimbursement for genetic testing
- Adoption and funding for genomic infectious disease surveillance
- Promoting STEM opportunities
Foster a responsible supply chain
Illumina’s global supply chain consists of suppliers, sub-contractors, channel partners, manufacturing sites, distribution centers, and customers. We consider it business-critical to work with suppliers who share our commitment to integrity and who support an ethical and compliant culture. We view our suppliers as partners in our effort to work toward a more equitable and sustainable future for all.
We hold our suppliers to the same standards of business conduct that we set for ourselves. We require them to comply with the standards of behavior outlined in our Supplier Code of Conduct and exhibit social responsibility and environmental stewardship.
2024 Corporate Social Responsibility Report
Learn about the progress we have made to shape a healthier future for all.